Table of Content

1. Report Overview
1.1 Global Cancer Immunotherapy Market Overview
1.2 Market Definition
1.3 Research Methodology
1.3.1 Primary Research
1.3.2 Secondary Research
1.3.3 Market Evaluation & Forecasting Methodology
1.4 Global Cancer Immunotherapy Market Segmentation
1.5 Overview of Findings
1.6 Why You Should Read This Report
1.7 How this report delivers?
1.8 Key Questions Answered by This Analytical Report
1.9 Frequently Asked Questions (FAQ)
1.10 Who is This Report For?

2. Introduction to Cancer Immunotherapy Market

3. Global Cancer Immunotherapy Market Forecast 2019 - 2029

4. Global Cancer Immunotherapy Market by Technology: Market Forecast 2019 - 2029
4.1 Overview
4.2 Monoclonal antibodies
4.3 Cytokines & Immunomodulators
4.4 Others (Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy)

5. Global Cancer Immunotherapy Market by Application: Market Forecast 2019 - 2029
5.1 Overview
5.2 Lung Cancer
5.3 Breast Cancer
5.4 Colorectal Cancer
5.5 Melanoma
5.6 Prostate Cancer
5.7 Head & Neck Cancer
5.8 Other Cancer types (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma)

6. Global Cancer Immunotherapy Market by End-User: Market Forecast 2019 - 2029
6.1 Hospitals
6.2 Cancer Research Centres
6.3 Clinics

7. Regional Cancer Immunotherapy Market Forecasts 2019-2029
7.1 Regional Cancer Immunotherapy Market Forecast 2018-2029
7.2 North American Cancer Immunotherapy Market Forecast 2018-2029
7.2.1 USA Cancer Immunotherapy Market Forecast 2018-2029
7.2.2 Canada Cancer Immunotherapy Market Forecast 2018-2029
7.2.3 Mexico Cancer Immunotherapy Market Forecast 2018-2029
7.3 South American Cancer Immunotherapy Market Forecast 2018-2029
7.3.1 Brazil Cancer Immunotherapy Market Forecast 2018-2029
7.3. 2 Argentina Cancer Immunotherapy Market Forecast 2018-2029
7.3.3 Paraguay Cancer Immunotherapy Market Forecast 2018-2029
7.3.4 Bolivia Cancer Immunotherapy Market Forecast 2018-2029
7.3.5 Rest of South America Cancer Immunotherapy Market Forecast 2018-2029
7.4 European Cancer Immunotherapy Market Forecast 2018-2029
7.4.1 France Cancer Immunotherapy Market Forecast 2018-2029
7.4.2 Germany Cancer Immunotherapy Market Forecast 2018-2029
7.4.3 UK Cancer Immunotherapy Market Forecast 2018-2029
7.4.4 Spain Cancer Immunotherapy Market Forecast 2018-2029
7.4.5 Italy Cancer Immunotherapy Market Forecast 2018-2029
7.4.6 Rest of Europe Cancer Immunotherapy Market Forecast 2018-2029
7.5 Asia-Pacific Cancer Immunotherapy Market Forecast 2018-2029
7.5.1 China Cancer Immunotherapy Market Forecast 2018-2029
7.5.2 Japan Cancer Immunotherapy Market Forecast 2018-2029
7.5.3 India Cancer Immunotherapy Market Forecast 2018-2029
7.5.4 Australia Cancer Immunotherapy Market Forecast 2018-2029
7.5.5 Thailand Cancer Immunotherapy Market Forecast 2018-2029
7.5.6 Rest of Asia-Pacific Cancer Immunotherapy Market Forecast 2018-2029
7.6 Rest of World Cancer Immunotherapy Market Forecast 2018-2029
7.6.1 Middle East Cancer Immunotherapy Market Forecast 2018-2029
7.6.2 Africa Cancer Immunotherapy Market Forecast 2018-2029
7.6.3 Other Countries Cancer Immunotherapy Market Forecast 2018-2029

8. Cancer Immunotherapy Market: Qualitative Analysis
8.1 Porter’s Five Forces Analysis of the Cancer Immunotherapy Market
8.2 Bargaining Power of Buyers (Low)
8.3 Bargaining Power of Suppliers (High)
8.4 Threat of New Entrants (Low)
8.5 Threat of Substitute Products (High)
8.6 Intensity of Competitive Rivalry (High)
8.7 Drivers & Restrains
8.8 Increasing Prevalence of Cancer
8.9 Increasing Research in Cancer Immunotherapy
8.10 High Cost of Cancer Immunotherapy
8.11 Increasing Funding for the Cancer Research by Governmental Organisations
8.12 Increasing Investment from Government, Public and Private Sector
8.13 Increased Focus Towards Advanced Treatment Protocols
8.14 Significant Unmet Need in Cancer Diagnosis
8.15 Increased Awareness to Reduce Healthcare Costs
8.16 Opportunities in Emerging Economies

9. Leading Companies in Cancer Immunotherapy Market
9.1 F. Hoffmann-La Roche AG
9.1.1 F. Hoffmann-La Roche AG: Company Overview
9.1.2 F. Hoffmann-La Roche AG: Business Performance
9.1.3 F. Hoffmann-La Roche AG: Product Portfolio
9.1.4 F. Hoffmann-La Roche AG: Recent Developments
9.2 Merck & Co., Inc.
9.2.1 Merck & Co., Inc.: Company Overview
9.2.2 Merck & Co., Inc.: Business Performance
9.2.3 Merck & Co., Inc.: Product Portfolio
9.2.4 Merck & Co., Inc.: Recent Development
9.3 Medtronic plc.
9.3.1 Medtronic plc.: Company Overview
9.3.2 Medtronic plc.: Business Performance
9.3.3 Medtronic plc.: Product Portfolio
9.3.4 Medtronic plc.: Recent Developments
9.4 Bristol-Myers Squibb
9.4.1 Bristol-Myers Squibb: Company Overview
9.4.2 Bristol-Myers Squibb: Business Performance
9.4.3 Bristol-Myers Squibb: Product Portfolio
9.4.4 Bristol-Myers Squibb: Recent Developments
9.5 Novartis AG
9.5.1 Novartis AG: Company Overview
9.5.2 Novartis AG: Business Performance
9.5.3 Novartis AG: Product Portfolio
9.5.4 Novartis AG: Recent Developments
9.6 Pfizer Inc.
9.6.1 Pfizer Inc.: Company Overview
9.6.2 Pfizer Inc.: Business Performance
9.6.3 Pfizer Inc.: Product Portfolio
9.6.4 Pfizer Inc.: Recent Developments
9.7 Bayer AG
9.7.1 Bayer AG: Company Overview
9.7.2 Bayer AG: Business Performance
9.7.3 Bayer AG: Product Portfolio
9.7.4 Bayer AG: Recent Development
9.8 AstraZeneca Plc.
9.8.1 AstraZeneca Plc.: Company Overview
9.8.2 AstraZeneca Plc.: Business Performance
9.8.3 AstraZeneca Plc.: Product Portfolio
9.9 Eli Lilly and Company
9.9.1 Eli Lilly and Company: Company Overview
9.9.2 Eli Lilly and Company: Business Performance
9.9.3 Eli Lilly and Company: Product Portfolio
9.9.4 Eli Lilly and Company: Recent Development
9.10 Advaxis, Inc.
9.10.1 Advaxis, Inc.: Recent Development
9.10.2 Advaxis, Inc.: Business Performance
9.10.3 Advaxis, Inc.: Recent Development

10. Conclusions
10.1 Current Leading Segments
10.2 Leading Regional Markets
10.3 Emerging Markets
10.4 The Future of the Market?

List of Tables


Table 2.1. Worldwide Estimated Incidence and Prevalence of all Cancer Types, (2012)
Table 3.1. Global Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%) 2018-2029
Table 4.1. Global Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%), 2018-2029
Table 4.2. Types of Monoclonal Antibodies
Table 4.3. Therapeutic Monoclonal Antibodies Approved by FDA
Table 4.4. Global Monoclonal Antibodies for Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 4.5. Global Monoclonal Antibodies for Cancer Immunotherapy Market Forecast by Geography: ($m, AGR%, CAGR%) 2018-2029
Table 4.6. Global Cytokines & Immunomodulators for Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 4.7. Global Cytokines & Immunomodulators for Cancer Immunotherapy Market Forecast by Geography:($m, AGR%, CAGR%), 2018-2029
Table 4.8. Global Others Technologies for Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 4.9. Global Other Technologies for Cancer Immunotherapy Market Forecast by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 5.1. Top Cancer Type in 2012
Table 5.2. Global Cancer Immunotherapy Market by Application: ($m, AGR%, CAGR%), 2018-2029
Table 5.3. Types of Monoclonal Antibodies
Table 5.4. Global Cancer Immunotherapy Market for Lung Cancer: ($m, AGR%, CAGR%), 2018-2029
Table 5.5. Global Cancer Immunotherapy Market for Lung Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 5.6. Global Cancer Immunotherapy Market for Breast Cancer: ($m, AGR%, CAGR%), 2018-2029
Table 5.7. Global Cancer Immunotherapy Market for Breast Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 5.8. Global Cancer Immunotherapy Market for Colorectal Cancer: ($m, AGR%, CAGR%), 2018-2029
Table 5.9. Global Cancer Immunotherapy Market for Colorectal Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 5.10. Global Cancer Immunotherapy Market for Melanoma Cancer: ($m, AGR%, CAGR%), 2018-2029
Table 5.11. Global Cancer Immunotherapy Market for Melanoma Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 5.12. Global Cancer Immunotherapy Market for Prostate Cancer: ($m, AGR%, CAGR%), 2018-2029
Table 5.13. Global Cancer Immunotherapy Market for Prostate Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 5.14. Global Cancer Immunotherapy Market for Head & Neck Cancer: ($m, AGR%, CAGR%), 2018-2029
Table 5.15. Global Cancer Immunotherapy Market for Head & Neck Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 5.16. Global Cancer Immunotherapy Market for Other Cancer types (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma): ($m, AGR%, CAGR%) 2018-2029
Table 5.17. Global Cancer Immunotherapy Market for Other Cancer Types (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma) by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 6.1. Global Cancer Immunotherapy Market by End-User: ($m, AGR%, CAGR%), 2018-2029
Table 6.2. Global Cancer Immunotherapy Market Forecast for Hospital: ($m, AGR%, CAGR%), 2018-2029
Table 6.3. Global Cancer Immunotherapy Market Forecast for Hospital by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 6.4. Funding Received by NCI ($m)
Table 6.5. Current Grants by Cancer Type as of August 2018
Table 6.6. Global Cancer Immunotherapy Market for Cancer Research Centres: ($m, AGR%, CAGR%), 2018-2029
Table 6.7. Global Cancer Immunotherapy Market Forecast for Cancer Research Centres by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 6.8. Global Cancer Immunotherapy Market Forecast for Clinic: ($m, AGR%, CAGR%), 2018-2029
Table 6.9. Global Cancer Immunotherapy Market Forecast for Clinic by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 7.1. Global Cancer Immunotherapy Market Forecast by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 7.2. North America Cancer Immunotherapy Market Forecast by Country: ($m, AGR%, CAGR%), 2018-2029
Table 7.3. North America Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%), 2018-2029
Table 7.4. North America Cancer Immunotherapy Market Forecast by Application: ($m, AGR%, CAGR%), 2018-2029
Table 7.5. North America Cancer Immunotherapy Market Forecast by End User: ($m, AGR%, CAGR%), 2018-2029
Table 7.6. US Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.7. Canada Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.8. Mexico Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.9. South America Cancer Immunotherapy Market Forecast by Country: ($m, AGR%, CAGR%), 2018-2029
Table 7.10. South America Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%), 2018-2029
Table 7.11. South America Cancer Immunotherapy Market Forecast by Application: ($m, AGR%, CAGR%), 2018-2029
Table 7.12. South America Cancer Immunotherapy Market Forecast by End User: ($m, AGR%, CAGR%), 2018-2029
Table 7.13. Brazil Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.14. Argentina Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.15. Paraguay Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.16. Bolivia Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.17. Rest of South America Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.18. European Cancer Immunotherapy Market Forecast by Country: ($m, AGR%, CAGR%), 2018-2029
Table 7.19. European Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%), 2018-2029
Table 7.20 European Cancer Immunotherapy Market Forecast by Application: ($m, AGR%, CAGR%), 2018-2029
Table 7.21 European Cancer Immunotherapy Market Forecast by End-User: ($m, AGR%, CAGR%), 2018-2029
Table 7.22. France Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.23. Germany Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.24. UK Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.25. Spain Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.26. Italy Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.27. Rest of European Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.28. Asia-Pacific Cancer Immunotherapy Market Forecast by Country: ($m, AGR%, CAGR%), 2018-2029
Table 7.29. Asia-Pacific Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%,), 2018-2029
Table 7.30. Asia-Pacific Cancer Immunotherapy Market Forecast by Application: ($m, AGR%, CAGR%), 2018-2029
Table 7.31 Asia-Pacific Cancer Immunotherapy Market Forecast by End- User: ($m, AGR%, CAGR%), 2018-2029
Table 7.32. China Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.33. Japan Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.34. India Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.35. Australia Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.36. Thailand Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.37. Rest of Asia-Pacific Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.38. Rest of World Cancer Immunotherapy Market Forecast by Country: ($m, AGR%, CAGR%), 2018-2029
Table 7.39. Rest of World Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%), 2018-2029
Table 7.40 Rest of World Cancer Immunotherapy Market Forecast by Application: ($m, AGR%, CAGR%), 2018-2029
Table 7.41 Rest of World Cancer Immunotherapy Market Forecast by End-User: ($m, AGR%, CAGR%), 2018-2029
Table 7.42. Middle East Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.43. Africa Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.44. Other Countries Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 9.1. F. Hoffmann-La Roche AG: Company Overview
Table 9.2. F. Hoffmann-La Roche AG: Product Portfolio
Table 9.3. F. Hoffmann-La Roche AG: Recent Developments
Table 9.4. Merck & Co., Inc.: Company Overview
Table 9.5. Merck & Co., Inc.: Product Portfolio
Table 9.6. Merck & Co., Inc.: Recent Development
Table 9.7. Medtronic plc.: Company Overview
Table 9.8. Medtronic plc.: Product Portfolio
Table 9.9. Medtronic plc.: Recent Developments
Table 9.10. Bristol-Myers Squibb: Company Overview
Table 9.11. Bristol-Myers Squibb: Product Portfolio
Table 9.12. Bristol-Myers Squibb: Recent Developments
Table 9.13 Novartis AG: Company Overview
Table 9.14. Novartis AG: Product Portfolio
Table 9.15. Novartis AG: Recent Developments
Table 9.16. Pfizer Inc.: Company Overview
Table 9.17. Pfizer Inc.: Product Portfolio
Table 9.18. Pfizer Inc.: Recent Development
Table 9.19. Bayer AG: Company Overview
Table 9.20. Bayer AG: Product Portfolio
Table 9.21. Bayer AG: Recent Development
Table 9.22. AstraZeneca Plc.: Company Overview
Table 9.23. AstraZeneca Plc.: Product Portfolio
Table 9.24. Eli Lilly and Company: Company Overview
Table 9.25. Eli Lilly and Company: Product Portfolio
Table 9.26. Eli Lilly and Company: Recent Development
Table 9.27. Advaxis, Inc.: Company Overview
Table 9.28. Advaxis, Inc.: Recent Developments
Table 10.1 Worldwide Estimated Prevalence of Cancer, 2012

List of Figures


Figure 1.1. Cancer immunotherapy Market Segmentation
Figure 2.1 Top winning Strategies of Market Players in Cancer Immunotherapy, 2014-2018
Figure 3.1 Cancer Immunotherapy Market by Technology: ($m), 2018-2029
Figure 3.2 Cancer Immunotherapy Market by Application: ($m), 2018-2029
Figure 3.3 Cancer Immunotherapy Market by End-User: ($m), 2018-2029
Figure 4.1 Cancer Immunotherapy Market by Technology: Market Share (%), 2018
Figure 4.2 Cancer Immunotherapy Market by Technology: Forecast ($m) 2018-2029
Figure 4.3 Global Monoclonal Antibodies for Cancer Immunotherapy Market Forecast by Geography: ($m) 2018-2029
Figure 4.4 Global Cytokines & Immunomodulators for Cancer Immunotherapy Market Forecast by Geography: ($m), 2018-2029
Figure 4.5 Global Other Technologies for Cancer Immunotherapy Market Forecast by Geography: ($m), 2018-2029
Figure 5.1. Global Cancer Immunotherapy Market by Application: ($m), 2018-2029
Figure 5.2. Global Cancer Immunotherapy Market by Application: Market Share (%), 2018
Figure 5.3. Global Cancer Immunotherapy Market for Lung Cancer Forecast by Geography: ($m), 2018-2029
Figure 5.4. Global Cancer Immunotherapy Market for Breast Cancer Forecast by Geography: ($m), 2018-2029
Figure 5.5. Global Cancer Immunotherapy Market for Colorectal Cancer Forecast, by Geography: ($m), 2018-2029
Figure 5.6. Global Cancer Immunotherapy Market for Melanoma Cancer Forecast by Geography: ($m), 2018-2029
Figure 5.7. Global Cancer Immunotherapy Market for Prostate Cancer Forecast, by Geography: ($m), 2018-2029
Figure 5.8. Global Cancer Immunotherapy Market for Head & Neck Cancer Forecast by Geography: ($m), 2018-2029
Figure 5.9. Global Cancer Immunotherapy Market for Other Cancer types (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma) Forecast by Geography: ($m), 2018-2029
Figure 6.0. Global Cancer Immunotherapy Market Forecast by End-User: ($m), 2018-2029
Figure 6.1 Global Cancer Immunotherapy Market by End-User: Market Share (%), 2018
Figure 6.2. Global Cancer Immunotherapy Market Forecast for Hospital by Geography: ($m), 2018-2029
Figure 6.3. Global Cancer Immunotherapy Market Forecast for Cancer Research Centres by Geography: ($m), 2018-2029
Figure 6.4 Global Cancer Immunotherapy Market Forecast for Clinic by Geography: ($m), 2018-2029
Figure 7.1. Global Cancer Immunotherapy Market Forecast by Geography: ($m), 2018-2029
Figure 7.2. Global Cancer Immunotherapy Market Forecast by Geography: Market Share (%), 2018
Figure 7.3. North America Cancer Immunotherapy Market by Country: Market Share (%), 2018
Figure 7.4. US Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.5. Estimation of diagnosis of Canadian Cancer Immunotherapy
Figure 7.6. Cancer Immunotherapy Market Forecast ($m), 2018-2029
Figure 7.7 Mexico Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.8 South America Cancer Immunotherapy Market Forecast by Country: ($m), 2018-2029
Figure 7.9 South America Cancer Immunotherapy Market by Country: Market Share (%), 2018
Figure 7.10. Brazil Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.11. Argentina Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.12. Paraguay Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.13. Bolivia Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.14. Rest of South America Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.15. Europe Cancer Immunotherapy Market Forecast by Country: ($m), 2018-2029
Figure 7.16. Europe Cancer Immunotherapy Market by Country: Market Share (%), 2018
Figure 7.17. France Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.18. Germany Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.19. UK Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.20. Spain Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.21. Italy Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.22. Rest of Europe Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.23. Asia-Pacific Cancer Immunotherapy Market Forecast by Country ($m) 2018-2029
Figure 7.24. Asia-Pacific Cancer Immunotherapy Market: Market Share (%), 2018
Figure 7.25. China Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.26. Japan Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.27. India Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.28. Australia Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.29. Thailand Cancer Immunotherapy Market Forecast: ($m,) 2018-2029
Figure 7.30. Rest of Asia-Pacific Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.31. RoW Cancer Immunotherapy Market Forecast by Country: ($m), 2018-2029
Figure 7.32. Rest of World Cancer Immunotherapy Market by Country: Market Share (%), 2018
Figure 7.33. Middle East Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.34. Africa Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.35. Other Countries Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 8.1 Porter’s Five Forces Analysis of the Cancer Immunotherapy Market
Figure 9.1. F. Hoffmann-La Roche AG: Historical Revenue: ($m), 2013-2017
Figure 9.2. F. Hoffmann-La Roche AG: Product Segments Share (%), 2017
Figure 9.3. F. Hoffmann-La Roche AG: Geographical Presence Share (%), 2017
Figure 9.4. Merck & Co., Inc.: Historical Revenue ($m), 2013–2017
Figure 9.5. Merck & Co., Inc.: Product Segments Share (%), 2017
Figure 9.6. Merck & Co., Inc.: Geographical Presence Share (%), 2017
Figure 9.7. Medtronic plc.: Historical Revenue ($m), 2014-2018
Figure 9.8. Medtronic plc.: Product Segments Share (%), 2018
Figure 9.9. Medtronic plc.: Geographical Presence Share (%), 2018
Figure 9.10. Bristol-Myers Squibb: Historical Revenue ($m), 2013-2017
Figure 9.11. Bristol-Myers Squibb: Product Segments Share (%), 2017
Figure 9.12. Bristol-Myers Squibb: Geographical Presence Share (%), 2017
Figure 9.13. Novartis AG: Historical Revenue ($m), 2013-2017
Figure 9.14. Novartis AG: Product Segments Share (%), 2017
Figure 9.15. Novartis AG: Geographical Presence Share (%), 2017
Figure 9.16. Pfizer Inc., Historical Revenue, ($m), 2013-2017
Figure 9.17. Pfizer Inc.: Product Segments Share (%), 2017
Figure 9.18. Pfizer Inc.: Geographical Presence Share (%), 2017
Figure 9.19. Bayer AG: Historical Revenue, ($m), 2013-2017
Figure 9.20. Bayer AG: Product Segments Share (%), 2017
Figure 9.21. Bayer AG: Geography Presence Share (%), 2018
Figure 9.22. AstraZeneca Plc.: Historical Revenue, ($m), 2013-2017
Figure 9.23. AstraZeneca Plc.: Product Segments Share (%), 2017
Figure 9.24. AstraZeneca Plc.: Geographical Presence Share (%), 2017
Figure 9.25. Eli Lilly and Company: Historical Revenue ($m), 2013-2018
Figure 9.26. Eli Lilly and Company: Product Segments Share (%), 2017
Figure 9.27. Eli Lilly and Company: Geographical Presence Share (%), 2017
Figure 9.28. Advaxis, Inc.: Historical Revenue ($m), 2014-2017
Figure 9.29. Advaxis, Inc.: Product Segments Share (%), 2017
Figure 10.1 World Cancer Immunotherapy by Technology: ($m), 2018-2029
Figure 10.2 World Cancer Immunotherapy by Application: ($m), 2018-2029
Figure 10.3 World Cancer Immunotherapy by End-User: ($m), 2018-2029
Figure 10.4 World Cancer Immunotherapy by Geography: ($m), 2018-2029